Trump Psychedelics Executive Order 2026: What Psilocybin and Ibogaine Mean for Veterans

# Trump Psychedelics Executive Order 2026: What Psilocybin and Ibogaine Mean for Veterans

> **Quick answer:** President Trump signed an executive order on April 18, 2026, directing the FDA to fast-track psilocybin and ibogaine as breakthrough therapies, unlocking $50 million in state research funding and a Right to Try pathway for seriously ill patients. The move targets the veteran suicide crisis — where more than 17 veterans die by suicide every single day — and marks the most significant federal shift on psychedelic-assisted therapy in decades.

Trump's psychedelics executive order signed April 18, 2026, is one of the most unexpected bipartisan moves of his second term. With Joe Rogan at his side, RFK Jr. as HHS Secretary in the room, and retired Navy SEAL Marcus Luttrell as a living argument for the policy, the White House put the full weight of the executive branch behind a class of substances that were Schedule I taboo just years ago. Here is exactly what happened, what the science says, and what it means for veterans and anyone watching the mental health treatment landscape.

## What Trump's Psychedelics Executive Order Actually Does

The executive order, titled "Accelerating Medical Treatments for Serious Mental Illness," is not a rescheduling order. Ibogaine and psilocybin remain Schedule I controlled substances under federal law. What the order does is methodically clear the bureaucratic path toward legal clinical use.

**FDA fast-track designations.** The order directs the FDA to issue Commissioner's National Priority Vouchers for psychedelics that already hold breakthrough therapy designation and to expedite rescheduling reviews the moment any substance completes Phase 3 trials and earns FDA approval.